The facility will now include reactor vessels with clean room product isolation and drying equipment to allow Highly Potent API manufacture up to 600kg batch size.
The expansion, which is attributable to the company’s selectAZyme technology, is believed to help in continued delivery of high quality API at competitive prices to its customers.
Almac, currently has 6 API and advanced chiral intermediates in Phase III clinical development,.
Almac VP business development Denis Geffroy said the capacity increase will enable a smooth transition from late phase clinical development to full commercialisation.
"Scale was becoming a limiting factor for some of our client projects and this new capacity is a strong commitment to offer project continuity," Geffroy added.